Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
100 patients will be randomized to receive Zerit (Stavudine) + Videx (Didanosine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).
Patients will be treated for 48 weeks.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Documented HIV infection.
CD4 cell count of 200 - 700 cells/mm3.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
AIDS defining condition within 1 month of study entry.
Prior Medication:
Excluded:
Patients with any history of antiretroviral therapy treatment.
Clareo Health | A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
